Filters

Pp-161 manufacturers

Filters

None products found

pp-161

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Major depressive disorder (MDD) in adults Clinical stage: Phase 3 Modality: Small molecule Mechanism / Target: Selective kappa opioid receptor (KOR) antagonist — blocks dynorphin-mediated KOR activation; reduces anhedonia, stress response and depressive-like behaviour; distinct from monoamine-based antidepressants Route / form: Oral tablet (once daily) Differentiation: Novel KOR mechanism; specifically addresses anhedonia — a core MDD symptom poorly served by SSRIs/SNRIs; no sexual dysfunction or weight gain expected; once-daily oral
Manufacturer #39188

Clinical-stage precision psychiatry company targeting validated neurobiological mechanisms in depression. Develops selective kappa opioid receptor antagonists with a differentiated mechanism of action. Wholly owned Phase 3 pipeline in major depressive disorder.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.